Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05280014 versus Herceptin with docetaxel and carboplatin in neoadjuvant HER2-positive breast cancer
2013-004679-11Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing PF-05280014 + Taxotere + carboplatin with Herceptin + Taxotere + carboplatin (2 arms). Primary endpoint: Percent of patients with cycle 5 trough concentration above 20 micrograms/mL. Started May 2014; status: completed.
02
Drugs
trastuzumab-qyyptrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004679-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004679-11.